July 15th 2025
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Limited Efficacy, Manageable Safety Profile Found With TAS-117 to Treat Ovarian and Breast Cancer
April 11th 2021TAS-117 showed limited clinical efficacy in treating patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.
Secondary Cytoreduction Followed by Chemotherapy May Improve PFS in Ovarian Cancer
April 9th 2021The phase 3 SOC-1 trial found an association between secondary cytoreduction followed by chemotherapy and prolonged progression-free survival when compared with chemotherapy alone for patients with relapsed ovarian cancer.
Long-Term OS Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost
April 5th 2021With more than 5 years of follow-up, results from the SOLO2 trial of olaparib maintenance in relapsed, high-grade serous or endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, were reported and showed superiority of the agent over placebo.
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer
March 20th 2021An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.
Adding Adavosertib to Gemcitabine Extends PFS and OS in Advanced High-Grade Serous Ovarian Cancer
March 3rd 2021In a phase 2 study, adavosertib plus gemcitabine showed signs of activity in platinum-resistant or platinum-refractory advanced high-grade serous ovarian cancer, including rare histological subtypes of ovarian cancer.
Racial Disparities in Palliative Care Use Found Among Patients with Ovarian and Cervical Cancer
February 7th 2021Data published in Data in Brief described an analysis that examined palliative care use among different racial and ethnic groups with metastatic gynecologic cancers, including ovarian, cervical, and uterine cancer.